7 recruiting, 4 completed, 3 active not recruiting. 14 Phase 2, 5 Phase 1.
By phase and status
Follow giredestrant: new trials by email Literature Review of giredestrant trials Research Report on giredestrant
Trials (filtered) newest first · largest first
All 14 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer GDC-4198, Giredestrant, Abemaciclib - Breast Cancer Phase 1 / Phase 2 Recruiting 285 2025-10-07 2026-10-26 A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer Inavolisib, Ribociclib, Letrozole - Breast Cancer Phase 2 Recruiting 120 2025-09-09 2026-10-26 NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer Abemaciclib 150 MG + Giredestrant 30 MG - Breast Cancer Phase 2 Recruiting 51 2025-01-27 2025-02-18 A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population Giredestrant, Abemaciclib, Inavolisib - Breast Cancer Phase 2 Active not recruiting 976 2024-04-01 2026-09-24 A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer Giredestrant, Triptorelin, Anastrozole - Breast Cancer Phase 2 Completed 231 2024-01-23 2026-02-24 Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% Giredestrant, Tamoxifen - Breast Cancer, Breast Cancer, Early-Onset Phase 2 Completed 92 2023-07-20 2026-03-19 A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer Giredestrant - Endometrial Cancer Phase 2 Completed 33 2023-06-27 2026-09-14 A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib - Endometrial Cancer Phase 1 / Phase 2 Recruiting 148 2021-10-20 2026-04-01 A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Ipatasertib, Cobimetinib, Trastuzumab Emtansine - Ovarian Cancer Phase 2 Active not recruiting 176 2021-10-07 2026-09-10 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Giredestrant, Abemaciclib, Ipatasertib - Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer Phase 1 / Phase 2 Recruiting 316 2021-06-22 2026-11-03 A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist - Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Phase 2 Active not recruiting 303 2020-11-27 2026-09-11 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors PF-07220060, Letrozole, Fulvestrant - Liposarcoma, Prostate Cancer Phase 1 / Phase 2 Recruiting 430 2020-09-23 2026-10-28 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) Giredestrant, Anastrozole, Palbociclib - Early Breast Cancer Phase 2 Completed 221 2020-09-04 2023-02-02 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer Capecitabine, Atezolizumab, Ipatasertib - Metastatic Breast Cancer Phase 1 / Phase 2 Recruiting 1132 2018-03-30 2026-11-06
Conditions studied Breast Neoplasms (10) · Endometrial Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Liposarcoma (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1)
Sponsors Hoffmann-La Roche (7) · MedSIR (2) · Alliance Foundation Trials, LLC. (1) · ETOP IBCSG Partners Foundation (1) · Fondazione Oncotech (1) · Genentech, Inc. (1) · Pfizer (1)
Countries United States (10) · Spain (9) · Germany (7) · South Korea (7) · Australia (6) · France (5) · Italy (5) · United Kingdom (5) · Brazil (4) · Canada (4) · Argentina (3) · China (3) · Israel (3) · Poland (3) · Russia (3)
Top investigators Antonio Llombart, MD (2) · Elisabetta Munzone, MD (1) · Michelino De Laurentiis, MD (1)
Results publications PMID 37657462 , PMID 38305868 , PMID 38537155 , PMID 40022843 , PMID 40896848
NIH funding 2023 (5) , 2017 (1) , 2025 (1)